Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Pathol Oncol Res · 2020 · PMC7471136 · PMID 32291570

Europe PMC DOI

hedged sentences

0.4620

closest p · 9.2× alpha

0.4620

boldest claim

The sentences

a numerical trendp = 0.462not close (p > 0.1)

the “lower 50%”, although there was a numerical trend towards longer OS with sunitinib-axitinib (median OS: 18.1 vs. 16.0 months; HR: 0.86 [0.56–1.29]; p = 0.462).

also in 1,012 other papers

did not reach statistical significanceno p-value reported

In patients with worse response to sunitinib, sunitinib-axitinib was associated with a trend towards greater OS compared to sunitinib-everolimus, but the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.